Few UK people likely to be suitable for new Alzheimer’s drugs when they come on stream
Few people in the UK with early stage Alzheimer’s disease are likely to be suitable for the latest drugs which aim to halt progress of the condition, yet many are nevertheless likely to be referred for these treatments, finds research published online in the Journal of Neurology Neurosurgery & Psychiatry.
The disease-modifying drugs, lecanemab and donanemab, slow cognitive decline in people with early stage Alzheimer’s disease. And they have been granted ‘breakthrough therapy’ ...











